MetaVia completes phase 1 trial of liver disease drug DA-1726
MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.
How this was made
The 30-second read
Why it matters
Completion of the Phase 1 final study visit and interim improvements in liver fat and metabolic measures can improve development confidence, but the next major catalyst is the full Parts 3A and 3B data release in 1Q 2027 and Phase 2 initiation in 2H 2027.
Market read
Traders may adjust biotech risk pricing based on Phase 1 completion and interim MRI-PDFF/weight/glycemic improvements, while awaiting final datasets.
What to watch
Key missing items include full adverse-event profile, durability beyond the 16-week regimen, and whether the extended Part 3A dosing changes tolerability or effect size.
Background
MetaVia is evaluating DA-1726, a once-weekly GLP-1/glucagon dual-receptor agonist, in Phase 1 for liver-related cardiometabolic diseases.
Ticker impact
MetaVia says the last patient completed Phase 1 final visit for DA-1726 and extended Part 3A to 24 weeks with updated dosing and interim MRI-PDFF results.
Likely near-term support as traders price improved probability of continued development, with upside capped until full Part 3A/3B data.
The article provides concrete interim efficacy metrics and trial completion, but does not include final datasets, adverse-event details, or Phase 2 outcomes.
Market effects
Adds incremental signal for GLP-1/glucagon dual agonist development in liver-related cardiometabolic disease, relevant to metabolic and NASH-adjacent biotech sentiment.
No direct regional market linkage beyond US biotech risk appetite.
Modest global relevance as it is a single-company Phase 1 update, not a cross-market regulatory or approval event.
Counterpoint
Interim Phase 1 MRI-PDFF and weight metrics may not translate into durable clinical endpoints; without full safety and efficacy, the market may fade the news.
Key entities
- companyMetaVia Inc.
NASDAQ-listed biotech developing DA-1726 for liver-related cardiometabolic diseases.
- drugDA-1726
Once-weekly GLP-1/glucagon dual-receptor agonist evaluated in Phase 1 Parts 3A and 3B.


